AptarGroup (ATR): Assessing Valuation After CARDAMYST Nasal Spray Milestone in Drug Delivery Solutions

AptarGroup (ATR) just notched an important milestone, as its Bidose nasal spray system is the delivery platform for newly FDA approved CARDAMYST, a PSVT treatment, marking Aptar’s first dual Bidose combination product.

See our latest analysis for AptarGroup.

The CARDAMYST win lands at a mixed moment for investors, with AptarGroup’s share price at $123.63 after a solid 7 day share price return, but still weaker year to date momentum and a modestly positive 3 year total shareholder return. This suggests long term compounding remains intact even as near term sentiment cools.

If AptarGroup’s latest healthcare move has your attention, it could be worth exploring other specialised healthcare stocks focused on building exposure to similar long term treatment trends.

With shares lagging year to date despite steady growth and a sizeable discount to analyst targets, is AptarGroup quietly undervalued after the CARDAMYST catalyst, or is the market already pricing in its next leg of expansion?

Most Popular Narrative: 23.4% Undervalued

Against AptarGroup’s last close of $123.63, the most widely followed narrative points to a materially higher fair value anchored in steady, compounding healthcare growth.

Ongoing investments in innovation, such as next-generation nasal and derma dispensing systems and expansion into active material sciences, are anticipated to capture share in both pharmaceuticals and high-growth dermacosmetic markets. This strengthens AptarGroup's market leadership and supports long-term top-line growth.

Read the complete narrative.

Curious how moderate growth, slight margin pressure, a shrinking share count, and a richer future earnings multiple can still justify a much higher valuation? The key assumptions behind that gap are all laid out in the narrative, from revenue trajectories to where the market multiple is expected to land. If you want to see exactly how those moving pieces compound into today’s fair value, you will need to dig into the full story.

Result: Fair Value of $161.43 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, ongoing IP litigation costs and uncertain demand for emergency medicine delivery systems could erode margins and stall the positive valuation narrative.

Find out about the key risks to this AptarGroup narrative.

Build Your Own AptarGroup Narrative

If these assumptions do not quite align with your view, you can dive into the numbers, shape your own thesis, and Do it your way in just minutes.

A good starting point is our analysis highlighting 3 key rewards investors are optimistic about regarding AptarGroup.

Ready for your next investing move?

Before you move on, lock in your next idea with targeted stock lists on Simply Wall St's screener so you do not miss tomorrow’s leaders.

• Capture early-stage potential by scanning these 3642 penny stocks with strong financials that already back their big stories with solid balance sheets and improving fundamentals.
• Position for the next wave of automation by focusing on these 26 AI penny stocks transforming everyday industries with scalable AI-driven business models.
• Research these 13 dividend stocks with yields > 3% that provide portfolio income through yields supported by resilient cash flows.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com